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Ulcerogenic potentialAbstract A series of novel 5-methyl-2-phenylthiazole-4-substituted-heteroazole derivatives (6–15)
have been synthesized. The structures of these compounds were established by IR, 1HNMR, Mass
spectral data and elemental analyses. Compounds were evaluated for their anti-inﬂammatory and
analgesic activities as well as gastric ulcerogenic effects. Derivatives 9, 10, 14 and 15 exhibited mod-
erate to good anti-inﬂammatory and analgesic activities in carrageenan-induced rat paw edema and
acetic acid-induced writhing in mice respectively, with low ulcerogenicity compared with the stan-
dard drug diclofenac sodium.
ª 2012 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Non-steroidal anti-inﬂammatory drugs (NSAIDs) are widely
used in the treatment of pain and inﬂammation. Most cur-
rently used NSAIDs have limitations for therapeutic uses,
since they cause gastrointestinal and renal side effects which
are inseparable from their pharmacological activities. These
compounds act via inhibition of the enzyme cyclooxygenase,
thus preventing prostaglandin synthesis. In the early 1990s, itwas discovered that the enzyme exists as two isomers, one con-
stitutive (COX-1) and the other inducible (COX-2) (Hla and
Neilson, 1992). COX-1 is an enzyme that is constitutively ex-
pressed and provides cytoprotection in the gastrointestinal
(GI) tract; whereas inducible COX-2 mediates inﬂammation
(Almansa et al., 2003). The traditional NSAIDs cause inhibi-
tion of both enzymes. In fact, most of them show greater selec-
tivity for COX-1 than COX-2 (Jackson and Hawkey, 1999).
Consequently long term therapy with nonselective NSAIDs
may cause gastrointestinal complications ranging from stom-
ach irritation to life-threatening GI ulceration and bleeding
(Allison et al., 1992). Therefore, selective COX-2 inhibitors
with better safety proﬁle have been marketed as a new gener-
ation of NSAIDs (Tally et al., 2000). But careful prospective
examination of coxibs has revealed unexpected cardiovascular
adverse effects (Dogne and Pratico, 2005).
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Synthesis and pharmacological evaluation of 5-methyl-2-phenylthiazole-4-substituted heteroazoles S47Most of the clinical NSAIDs possess acidic carboxyl
(COOH) group, which further cause GI irritation by direct
contact of –COOH group in GIT at doses very close to anti-
inﬂammatory ones. These serious side effects limit the use ofNSAIDs as a safer drug for the treatment of inﬂammation.
Several studies have described the derivatization of the carbox-
ylate function of representative NSAID with less acidic azoles:
thiazole (Giri et al., 2009), oxadiazole (Akhter et al., 2009),
S48 S.N. Thore et al.thiadiazole (Aktay and Salgın-Go¨ksen, 2007) etc. which
resulted in an increased antiinﬂammatory activity with reduced
ulcerogenicity. In our attempt to synthesize new, safer and
potent agents for treatment of inﬂammatory diseases, we used
5-methyl 2-aryl-thiazole moiety. This heterocyclic system has
found application in drug development for the treatment
of inﬂammation. Fentiazac (2-phenyl-thiazole), Meloxicam
(2-methyl-thiazole), Fanetizole (2-phenyl-thiazole), Meloxi-
cam (2-methyl-thiazole), and Fanetizole (2-amino-thiazole)
(Rehman et al., 2005; Potewar et al., 2007) are some examples
of thiazole bearing anti-inﬂammatory products. Various non
acidic (Amir et al., 2007) and acid bioesters of the type of 1,3,
4-thiadiazole and 1,3,4-oxadiazole derivatives (Manjunathaa
et al., 2010) were reported for anti-inﬂammatory activity. With
the aim of obtaining new anti-inﬂammatory agents, we have
replaced carboxylic acid group of 5-methyl-2-phenylthiazole
scaffold with non acidic or less acidic heterocycles like 1,3,
4-oxadiazole, 1,3,4-oxadiazolinone 1,3,4-oxadiazolinethione,
tetrazole and pyrazole moiety at position 4 of thiazole.
The present work describes the synthesis of some new 5-
methyl-2-phenylthiazole-4-substituted-heteroazole derivatives
( Schemes 1 and 2). Their antiinﬂammatory and analgesic
activities were recorded. Synthesized compounds were charac-
terized on the basis of their spectral data.
2. Experimental
2.1. General
The progress of reactions was monitored on aluminum silica
gel 60 F254 (Merck) using chloroform–methanol (9:1 by vol-
ume) as an eluent. Iodine vapors and UV light (wavelength
254 nm) were used as visualizing agents. Melting points were
recorded on a Buchi capillary melting point apparatus and
are uncorrected. IR spectra were recorded on a Perkin-Elmer
157 spectrometer using KBr pellets. The 1HNMR spectra were
recorded on a Bucker WM-400 (400 MHz FT NMR) spectro-
photometer using CDCl3 and DMSO-d6 as solvents with TMS
as an internal reference. Chemical shifts (d) are expressed in
ppm. Mass spectra were obtained on a JEOL-SX-102 instru-
ment using electron impact ionization. Elemental analyses
were performed on Perkin Elmer Auto system 240c analyzer
and were within ±0.4% of the theoretical values. The chemi-
cals were purchased from Aldrich and Merck. Reagents and
solvents were of analytical grade.
2.2. Chemistry
2.2.1. Synthesis of 5-methyl-2-phenylthiazole-4-carboxylic acid
ethyl ester(2) (Michael and Andrew, 2007)
Thiobenzamide 1 (4.0 g, 29.1 mmol) and ethyl 2-chloroace-
toacetate (4.74 g, 29.1 mmol) were dissolved in 40 ml ethanol.
The reaction mixture was reﬂuxed for 12 h. The excess of eth-
anol was removed under reduced pressure to yield semisolid,
which was puriﬁed by ﬂash chromatography eluting with hex-
ane–ethyl acetate (1:1) to provide yellow solid.
Yield: 6.0. g (83%); mp: 74–77 C (74–75 C lit.); IR (KBr,
cm1): 3015 (Ar–CH), 1740 (C‚O of ester); 1H NMR
(400 MHz, CDCl3) d ppm: 1.35 (t, 3H, CH3), 2.65 (s, 3H,
CH3) 4.33 (q, 2H, CH2)7.52–8.00 (m, 5H, Ar–H); MS (EI)
m/z: 248 [M+1].2.2.2. Synthesis of 5-methyl-2-phenylthiazole-4-carbohydrazide
(3) (Danil et al., 2008)
5-Methyl-2-phenylthiazole-4-carboxylic acid ethyl ester 2
(3.0 g, 12.0 mmol) was dissolved in 30 ml ethanol, to this
hydrazine hydrate (1.81 g, 36.0 mmol) was added and reﬂuxed
for 12 h. The reaction mixture was cooled and solid appeared
in the ﬂask was ﬁltered and recrystallized from ethanol to yield
white crystalline product.
Yield: 2.4 g (85%); mp: 166–169 C (168–169 C lit.); IR
(KBr, cm1): 3350, 3215 (NH2), 3140 (NH), 1677 (C‚O of
amide); 1H NMR (400 MHz, DMSO d6) d ppm: 2.73 (s, 3H,
CH3), 4.47 (bs, 2H, NH2), 7.36–8.10 (m, 5H, Ar–H), 8.65
(bs, 1H, NH); MS (EI) m/z: 234 [M+1].
2.2.3. Synthesis of 5-methyl-2-phenylthiazole-4-carboxamide (4)
5-Methyl-2-phenylthiazole-4-carboxylic acid ethyl ester 2 (1.0 g,
4.00 mmol) was dissolved in 10 ml of acetonitrile. To this, conc.
ammonia (10 ml) was added dropwise and reactionmixture was
heated on awater bath at 50–60 C for 6 h. The reactionmixture
was cooled and poured into ice water. The solid obtainedwas ﬁl-
tered, dried and recrystallized from ethanol.
Yield: 0.75 g (86%); mp:175–178 C; IR (KBr, cm1): 3420,
3215 (NH2), 3020 (Ar–CH), 1670 (C‚O of amide);
1H NMR
(400 MHz, CDCl3) d ppm: 2.70 (s, 3H, CH3), 4.92 (bs, 2H,
NH2), 7.41–8.14 (m, 5H, Ar–H); MS (EI) m/z: 219 [M+1].
2.2.4. Synthesis of 5-methyl-2-phenylthiazole-4-carbonitrile (5)
To the solution of 5-methyl-2-phenylthiazole-4-carboxamide 4
(0.5 g, 2.2 mmol) in 10 ml dimethylformamide, oxalyl chloride
(0.43 g, 3.44 mmol) was added at 0–5 C and the reaction mix-
ture stirred at 0-5 C for 30 min. Then pyridine (0.54 g,
6.88 mmol) was added and stirred again for 10 min. The reac-
tion mixture was poured on ice water and extracted with dichlo-
romethane. The organic layer concentrated to get white crystals.
Yield: 0.34 g (76%); mp: 110–113 C; IR (KBr, cm1): 3025
(Ar–CH), 2235 (CN); 1H NMR (400 MHz, CDCl3) d ppm:
2.68 (s, 3H, CH3), 7.46–8.12 (m, 5H, Ar–H); MS (EI) m/z:
201 [M+1].
2.2.5. Synthesis of 5-methyl-2-phenyl-4-(1H-tetrazol-5-yl)
thiazole (6)
5-Methyl-2-phenylthiazole-4-carbonitrile 5 (0.25 g, 1.25 mmol),
trimethylsilyl azide (0.28 g, 2.50 mmol) and dibutyltin (20 mg)
in 10 ml toluene were heated under reﬂux for 16 h. The excess
of toluene was removed under reduced pressure and the residue
was triturated with water. The solid product formed was ﬁltered
off and recrystallized from ethanol to yield white crystals.
Yield: 0.11 g (50%); mp: 190–193 C; IR (KBr, cm1):3305
(NH), 3030 (Ar–CH), 1630 (C‚N); 1H NMR (400 MHz,
CDCl3) d ppm: 2.72 (s, 3H, CH3), 7.36–8.05(m, 5H, Ar–H);
MS (EI) m/z: 244 [M+1]; Anal. Cald. for C11H9N5S: C,
54.31; H, 3.73; N, 28.79. Found: C, 54.30; H, 3.69; N, 28.74.
2.2.6. Synthesis of 2-(5-methyl-2-phenylthiazole-4-yl)-[1,3,4]
oxadiazole (7)
A mixture of 3 (0.25 g, 1.0 mmol) and triethylorthoformate
(5 ml) was reﬂuxed for 10 h. The excess of the solvent was
distilling off under reduced pressure and the solid product
obtained was ﬁltered and recrystallized from ethanol to yield
white crystalline product.
Synthesis and pharmacological evaluation of 5-methyl-2-phenylthiazole-4-substituted heteroazoles S49Yield: 0.22 g (85%); mp: 210–213 C; IR (KBr, cm1):3025
(Ar–CH), 1615 (C‚N); 1H NMR (400 MHz, DMSO d6) d
ppm: 2.60 (s, 3H, CH3), 7.34–7.97 (m, 5H, Ar–H),8.40 (s,
1H, oxadiazole-H); MS (EI) m/z: 244 [M+1]. Anal. Cald.
for C12H9N3OS: C, 59.24; H, 3.73; N, 17.27. Found: C,
59.21; H, 3.72; N, 17.22.
2.2.7. Synthesis of 5-(5-methyl-2-phenylthiazole-4-yl)-[1,3,4]
oxadiazole-2-amine (8)
Sodium bicarbonate (0.1 g, 1.2 mmol) in 5 ml of water was
added to a solution of 3 (0.25 g, 1.0 mmol) in 10 ml of dioxane
at room temperature. After 5 min, cyanogens bromide
(0.136 g, 1.2 mmol) was added. After 4 h of room temperature
stirring, the solid obtained was ﬁltered and dried in vacuum.
The solid was recrystallized from isopropyl alcohol to yield
brown colored product.
Yield: 0.18 g (67%); mp: 222–225 C; IR (KBr, cm1):
3385, 3130 (NH2), 3020 (Ar–CH), 1620 (C‚N);
1H NMR
(400 MHz, DMSO d6) d ppm: 2.67 (s, 3H, CH3), 7.36 (bs,
2H, NH2),7.52–7.97 (m, 5H, Ar–H); MS (EI) m/z: 259
[M+1]. Anal. Cald. for C12H10N4OS: C, 55.80; H, 3.90; N,
21.69. Found: C, 55.75; H, 3.91; N, 21.73.
2.2.8. Synthesis of 5-(5-methyl-2-phenylthiazole-4-yl)-1,3,4-
oxadiazole-2(3H)-one (9)
A mixture of 3 (0.25 g, 1.0 mmol) and N,N0-carbonyldiimidaz-
ole (0.26 g, 1.61 mmol) in 10 ml dioxane was heated under re-
ﬂux for 4 h. After cooling, the solvent was removed under
reduced pressure and the residue was triturated with water.
The solid product formed was ﬁltered off and recrystallized
from ethanol to yield colorless crystals.
Yield: 0.20 g (74%); mp: 141–144 C; IR (KBr, cm1):3175
(NH), 3010 (Ar–CH), 1680 (C‚O), 1620 (C‚N);
1H NMR (400 MHz, DMSO d6) d ppm: 2.71 (s, 3H, CH3),
7.43–7.95 (m, 5H, Ar–H), 9.42 (s, 1H, NH); MS (EI) m/z: 260
[M+1]. Anal. Cald. for C12H9N3O2S: C, 55.59; H, 3.50; N,
16.21. Found: C, 55.56; H, 3.51; N, 16.22.
2.2.9. Synthesis of 5-(5-methyl-2-phenylthiazole-4-yl)-1,3,4-
oxadiazole-2(3H)-thione (10)
A mixture of 3 (0.5 g, 0.21 mmol) and carbon disulﬁde (3 ml)
in 10 ml of pyridine was heated under reﬂux for 5 h with stir-
ring. After cooling, the solvent was evaporated under reduced
pressure and the residue was triturated with an ice-water mix-
ture. The separated solid product was ﬁltered, washed with
water, dried and recrystallized from isopropyl alcohol to af-
ford 10 as pale yellow crystals.
Yield: 0.48 g (81%); mp: 235–238 C; IR (KBr, cm1): 3212
(NH), 3015 (Ar–CH), 1625 (C‚N), 1310 (C‚S); 1H NMR
(400 MHz, DMSO d6) d ppm: 2.67(s, 3H, CH3), 7.53–8.00
(m, 5H, Ar–H),9.57 (s, 1H, NH); MS (EI) m/z: 276 [M+1].
Anal. Cald. for: C12H9N3OS2: C, 52.35; H, 3.29; N, 15.26.
Found: C, 52.33; H, 3.32; N, 15.22.
2.2.10. Synthesis of 4-{2-[5-(5-methyl-2-phenylthiazole-4-yl)-
1,3,4-oxadiazole-2-ylthio]-ethyl}-morpholine (11)
A mixture of the oxadiazolinethione 10 (0.2 g, 0.72 mmol),
fused sodium acetate (0.31 g, 3.8 mmol) and 4-(2-chloroethyl)
morpholine hydrochloride (0.14 g, 0.72 mmol) in 10 ml of eth-
anol was heated under reﬂux for 10 h with stirring. The solvent
was removed under reduced pressure and the residue was trit-urated with water. The solid product formed was ﬁltered off
and recrystallized from ethanol to yield white crystals.
Yield: 0.18 g (54%); mp: 134–137 C; IR (KBr, cm1):3015
(Ar–CH), 1622(C‚N);); 1H NMR (400 MHz, DMSO d6) d
ppm: 2.36–2.45 (m, 4H, NCH2), 2.62 (s, 3H, CH3), 2.78 (t,
2H, SCH2CH2N), 3.17 (t, 2H, SCH2CH2N), 3.43 (t, 4H,
OCH2), 7.39–8.10 (m, 5H, Ar–H); MS (EI) m/z: 389 [M+1].
Anal. Cald. for: C18H20N4O2S2: C, 55.65; H, 5.19; N, 14.42.
Found: C, 55.64; H, 5.12; N, 14.46.
2.2.11. Synthesis of dimethyl-{2-[5-(5-methyl-2-phenylthiazole-
4-yl)-1,3,4-oxadiazole-2-ylthio]-ethyl}-amine (12)
Prepared from compound 10 (0.2 g, 0.72 mmol), fused sodium
acetate (0.31 g, 3.8 mmol) and 2-dimethylaminoethyl chloride
hydrochloride (0.11 g, 0.72 mmol) by using the same procedure
as mentioned in 11.
Yield: 0.17 g (68%); mp: 131–134 C; IR (KBr, cm1):3030
(Ar–CH),1628 (C‚N); 1H NMR (400 MHz, DMSO d6) d
ppm: 7.49–8.13 (m, 5H, Ar–H), 3.28 (t, 2H, SCH2CH2N),
2.82 (t, 2H, SCH2CH2N), 2.65 (s, 3H, CH3),2.20 (s, 6H,
N(CH3)2); MS (EI) m/z: 347 [M+1]. Anal. Cald. for:
C16H18N4OS2: C, 55.47; H, 5.24; N, 16.17. Found: C, 55.44;
H, 5.22; N, 16.12.
2.2.12. Synthesis of 5-(5-methyl-2-phenylthiazole-4-yl)-3-
(piperidin-1-yl-methyl)-1,3,4-oxadiazole-2(3H)-thione (13)
To a solution of 1,3,4-oxadiazol-5-thione 10 (0.2 g, 0.72 mmol)
in ethanol, a mixture of formaldehyde (0.2 g, 0.14 mmol) and a
piperidine (0.065 g, 0.72 mmol) in ethanol was added with stir-
ring. After complete addition, the stirring was continued over-
night at room temperature. The separated white solid product
was ﬁltered, washed with water, dried and recrystallized from
ethanol.
Yield: 0.15 g (60%); mp:251–254 C; IR (KBr, cm1):3030
(Ar–CH), 1615 (C‚N),1305 (C‚S); 1H NMR (400 MHz,
DMSO d6) d ppm: 7.42–8.00 (m, 5H, Ar–H), 4.87 (s, 2H,
N–CH2–N), 3.32 (t, 4H, piperidine-CH2), 2.20 (q, 2H, piperidine
CH2), 2.64 (s, 3H, CH3),1.90 (q, 4H, piperidine-CH2); MS (EI)
m/z: 373 [M+1]. Anal. Cald. for: C18H20N4OS2: C, 50.04; H,
5.41; N, 15.04. Found: C, 50.00; H, 5.38; N, 15.00.
2.2.13. Synthesis of (5-amino-4-ethylester-1H-pyrazol-1-yl)(5-
methyl-2-phenylthiazole-4-yl)-methanone (14)
A mixture of 3 (0.25 g, 1.07 mmol) and ethyl(ethoxymethylene)
cyanoacetate (0.18 g, 1.07 mmol) in 10 ml of ethanol was
heated under reﬂux for 6 h. The reaction mixture was cooled
and poured over crushed ice. The separated white solid was ﬁl-
tered, washed with water and recrystallized from ethanol.
Yield: 0.27 g (71%); mp: 182–185 C; IR (KBr, cm1):
3350, 3185 (NH2), 3030 (Ar–CH), 1720 (C‚O), 1625
(C‚N); 1H NMR (400 MHz, DMSO d6) d ppm: 8.99 (s, 1H,
pyrazole-H), 7.40 (bs, 2H, NH2), 7.55–7.87 (m, 5H, Ar–H),
4.24 (q, 2H, CH2), 2.68 (s, 3H, CH3), 1.30 (t, 3H, CH3); MS
(EI) m/z: 357 [M+1]. Anal. Cald. for: C17H16N4O3S: C,
57.29; H, 4.53; N, 15.72. Found: C, 57.27; H, 4.54; N, 15.70.
2.2.14. Synthesis of (5-amino-3-phenyl-1H-pyrazol-1-yl)
(5-methyl-2-phenylthiazol-4-yl)-methanone (15)
Prepared from compound 3 (0.25 g, 1.07 mmol) and benzoyl
acetonitrile (0.155 g, 1.07 mmol) by using the same procedure
as mentioned in 14.
S50 S.N. Thore et al.Yield: 0.31 g (82%); mp: 210–213 C; IR (KBr, cm1):
3378, 3212 (NH2), 3020 (Ar–CH), 1695 (C‚O), 1610
(C‚N); 1H NMR (400 MHz, DMSO d6) d ppm: 8.10 (s, 1H,
pyrazole-H), 7.82–7.87 (m, 5H, Ar–H), 7.40–7.55 (m, 5H,
Ar–H), 7.24 (bs, 2H, NH2), 2.62 (s, 3H, CH3); MS (EI) m/z:
361 [M+1]; Anal. Cald. for C20H16N4OS: C, 66.65; H, 4.47;
N, 15.54. Found: C, 66.62; H, 4.41; N, 15.51.
3. Pharmacological evaluation
Synthesized compounds ( 6–15) were investigated for anti-
inﬂammatory and analgesic activities and most active repre-
sentatives ( 9, 10, 14 and 15) of the series were investigated
for acute ulcerogenicity. Diclofenac sodium was used as a ref-
erence standard at a dose 25 mg/kg for anti-inﬂammatory
analgesic and ulcerogenicity studies. The experiments were
performed on Albino rats of Wistar strain of either sex, weigh-
ing 180–200 g for anti-inﬂammatory activity and Albino mice
of either sex weighing 25–30 g for analgesic activity. The ani-
mals were divided into groups (control, reference and test
groups) of 6 animals each. The tested compounds and the stan-
dard drugs were administered in the form of a suspension
(using 1% carboxymethylcellulose) in distill water by oral
route of administration for analgesic, anti-inﬂammatory and
ulcerogenicity studies. The animals were maintained in colony
cages at 25 ± 2 C, relative humidity 45–55%, under a 12 h
light–dark cycle; they were fed standard animal feed. All the
animals were acclimatized for a week before use.
3.1. Anti-inﬂammatory activity
Anti-inﬂammatory activity was evaluated using carrageenan
induced rat paw edema method (Winter et al., 1962). Carra-
geenan solution (0.1% in sterile 0.9% NaCl solution) in a vol-
ume of 0.1 mL was injected subcutaneously into the subplantar
region of the right hind paw of each rat. One group was kept as
control and the animals of the other group were pretreated
with the test drugs and standard drug 1 h before the carra-
geenan treatment. The paw volume of the all groups of rats
was measured using the mercury displacement technique with
the help of digital plethysmometer (UGO BASIL, ITALY)
immediately before and 1, 2 and 3 h after carrageenan injec-Table 1 Results of anti-inﬂammatory activity of title compounds (
Compound Change in paw volume in (ml) after drug treatment (±S
0 h 1 h 2 h
Control 0.38 ± 0.03* 0.48 ± 0.04* 0.57 ± 0.09*
Diclofenac 0.27 ± 0.10* 0.33 ± 0.01 * 0.36 ± 0.10*
6 0.29 ± 0.04* 0.35 ± 0.04* 0.41 ± 0.10*
7 0.28 ± 0.06* 0.36 ± 0.07* 0.41 ± 0.08*
8 0.26 ± 0.06 0.34 ± 0.10* 0.40 ± 0.07*
9 0.31 ± 0.02* 0.38 ± 0.03* 0.42 ± 0.03*
10 0.33 ± 0.06* 0.38 ± 0.09* 0.42 ± 0.08*
11 0.35 ± 0.03* 0.42 ± 0.08* 0.47 ± 0.06*
12 0.37 ± 0.02* 0.44 ± 0.07* 0.50 ± 0.07*
13 0.30 ± 0.07* 0.37 ± 0.08* 0.41 ± 0.09*
14 0.34 ± 0.07* 0.40 ± 0.05* 0.42 ± 0.02*
15 0.39 ± 0.09* 0.45 ± 0.06* 0.49 ± 0.05*
Data analyzed by one-way ANOVA followed by Dunnett’s test, (n= 6)
* P< 0.05 signiﬁcant from control. Dose levels: test compounds and diction. The edema was expressed as a mean reduction in paw
volume (ml) after treatment with tested compounds and the
percent of edema inhibition was obtained as follows:
Percent inhibition ¼ ðVt VcÞcontrol ðVt VcÞtested
compound=ðVt VcÞcontrol 100
where Vt = volume of edema at speciﬁc time interval and
Vc = volume of edema at zero time interval.
The results are presented in Table 1.
3.2. Analgesic activity
Analgesic activity was evaluated using acetic acid induced
writhing method (Koster et al., 1959). After 50 min of the oral
administration of test compound and standard drug, each ani-
mal was injected with 0.25 ml of 0.6% v/v acetic acid solution
intraperitoneally. After 10 min of acetic acid injection, the
numbers of muscular contractions (writhings) in mice were
counted for a period of 15 min. A signiﬁcant reduction in the
number of writhing by any treatment as compared to control
animals was considered as a positive analgesic response. The
average number of writhes in each group of treated mice was
compared with that of the control. The % analgesic activity
was expressed according to the formula:
% inhibition ¼ ½n n0=n 100
where; n is the number of writhes in control group of mice and
n0 is the number of writhes in test and standard group of mice.
The observations are tabulated as Table 2.
3.3. Evaluation of ulcerogenicity index
Ulceration in rats was induced as described by (Goyal et al.,
1985). Albino rats of the Wistar strain weighing 150–200 g of
either sex were divided into various groups, each of six ani-
mals. Control group of animals was administered only 1% car-
boxymethylcellulose solution in water. One group was
administered with diclofenac sodium at a dose of 25 mg/kg
once daily for four days. The remaining group of animals
was administered with test compounds at a dose of 25 mg/
kg. On the ﬁfth day, pylorus was ligated as per the method
of (Shay et al., 1945). Animals were fasted for 24 h before6–15) against carrageenan induced rat paw edema model in rats.
EM) Anti-inﬂammatory activity (% inhibition)
3 h 1 h 2 h 3 h
0.66 ± 0.04* – – –
0.39 ± 0.08* 40 52.63 57.14
0.46 ± 0.01* 30 36.84 39.28
0.47 ± 0.11* 20 31.57 32.14
0.45 ± 0.06* 20 26.31‘ 32.14
0.46 ± 0.05* 30 42.10 53.57
0.44 ± 0.09* 50 52.63 60.71
0.52 ± 0.09* 30 36.84 35.71
0.55 ± 0.05* 30 31.57 35.71
0.46 ± 0.07* 30 42.10 42.85
0.44 ± 0.07* 40 57.89 64.28
0.53 ± 0.03* 40 47.36 50
.
lofenac sodium (25 mg/kg, b.w. p.o.).
Table 2 Analgesic activity of title compounds (6–15) against
acetic acid induced writhing tests in mice.
Compound No. of writhes in 15 min
after treatment (mean ± SEM)
% Inhibition
Control 32.50 ± 0.94* –
Standard 13.66 ± 0.50* 57.96
6 20.75 ± 0.62* 36.15
7 24.25 ± 0.45* 25.38
8 25.50 ± 0.61* 21.53
9 22.40 ± 0.95* 56.30
10 12.85 ± 0.94* 60.46
11 22.40 ± 0.72* 31.07
12 22.25 ± 0.91* 31.53
13 17.33 ± 0.78* 46.67
14 12.12 ± 1.00* 62.70
15 12.75 ± 0.73* 60.76
Data analyzed by one-way ANOVA followed by Dunnett’s test,
(n= 6),
Dose levels: Test compounds and diclofenac sodium (25 mg/kg b.w.
p.o).
* P< 0.05 signiﬁcant from control.
Table 3 Evaluation of ulcerogenicity index.
Compound Dose mg/kg/day (p.o.) Time (days) Ulcer index
Control CMC 1%w/v 4 –
Diclofenac 25 4 3.32 ± 0.74*
9 25 4 1.11 ± 0.79*
10 25 4 0.77 ± 0.51*
14 25 4 0.79 ± 0.53*
15 25 4 0.86 ± 0.40*
Data analyzed by one-way ANOVA followed by Dunnett’s test,
(n= 6),
* P< 0.05 signiﬁcant from control.
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animals were sacriﬁced. The stomach was removed and opened
along with the greater curvature. Ulcer index was determined
by the method of (Ganguly and Bhatnagar, 1973) and is re-
corded in (Table 3).
3.4. Statistical analysis
Statistical analysis of the biological activity of the synthesized
compounds was evaluated using a one-way analysis of vari-
ance (ANOVA). In all cases, post hoc comparisons of the
means of individual groups were performed using Dunnett’s
test. A signiﬁcance level of P< 0.05 denoted signiﬁcance in
all cases. All values are expressed as mean ± SEM. Statistical
analysis was carried out using Graph Pad Prism (Graph Pad
Prism 3.0 version).
4. Result and discussion
4.1. Chemistry
Synthesis of title compounds (6–15) is outlined in (Schemes 1
and 2). The parent compound 5-methyl-2-phenylthiazole-4-carboxylic acid ethyl ester (2) was synthesized by the reaction
of thiobenzamide (1) with ethyl-2-chloroacetoacetate in etha-
nol. The compound (2) on reﬂux with conc. ammonia solution
in the acetonitrile led to the formation of 5-methyl-2-
phenyl-thiazole-4-carboxamide (4), which on further treatment
with oxalyl chloride in DMF afforded 5-methyl-2-phenyloxaz-
ole-4-carbonitrile (5). The compound (5) possessess cyano
group and can be conveniently converted into tetrazole deriv-
ative (6) by treatment with trimethylsilylazide in the presence
of dibutyltin at reﬂux temperature.
The compound (2) on treatment with hydrazine hydrate
afforded 5-methyl-2-phenylthiazole-4-carboxhydrazide (3).
The acid hydrazide compound (3) was shown to be a key inter-
mediate for the synthesis of several azoles. 1,3,4-Oxadiazole (7)
was prepared by the reaction of acid hydrazide (3) with tri-
ethylorthoformate. The 2-amino-l,3,4-oxadiazoles (8) resulted
from the action of cyanogens bromide and sodium bicarbonate
on acid hydrazide (3).
The 1,3,4-oxadiazol-2-one (9) was obtained by treatment of
the acid hydrazide (3) with 1,10-carbonyldiimidazole (CDI) in
reﬂuxing dioxane. The acid hydrazide (3) was then subjected
to cyclization with carbon disulﬁde in boiling pyridine to af-
ford the corresponding 1,3,4-oxadiazol-2-thione (10). Alkyl-
ation of 1,3,4-oxadiazol-2-thione (10) with alkylating agents
such as 4-(2-chloroethyl)morpholinyl hydrochloride or 2-
dimethyaminoethyl chloride hydrochloride in boiling ethanol
in the presence of fused sodium acetate gave independently re-
quired compounds which have been assigned the structures
(11) and (12), respectively. The resultant 1,3,4-oxadiazol-2-thi-
ones (11) were further converted into corresponding mannich
bases (13) on aminomethylation with formaldehyde and
piperidine.
Finally, acid hydrazide (3) on reaction with ethyl (ethoxym-
ethylene) cyanoacetate in ethanol gave the corresponding
5-amino-4-ethylester pyrazole derivatives (14). The 5-amino-
3-phenylpyrazole derivative (15) was isolated by the reaction
of (3) with benzoylacetonitrile.
The structures of various synthesized compounds were as-
signed on the basis of spectral studies and it was reported in
experimental protocols. The IR spectral characteristics of
compounds (6–15) showed absorption bands ranging from
3130–3385 cm1 for NH2, 3212–3175 cm
1 for NH, 3015–
3030 cm1 for Ar–H, 1615–1630 cm1 for C‚N and
1305–1310 cm1 for C‚S. For 1,3,4-oxadiazole derivatives
(7–13), the presence of C‚N stretching band at 1615–
1630 cm1 is an evidence of ring closure. Oxadiazole (9 and
10) showed N–H stretching bands at 3175–3212 cm1. The ab-
sence of absorptions of the amide carbonyl in the region
1670 cm1 and hydrazide in the region 3215–3350 cm1 indi-
cated the formation of azoles (6–14) from the corresponding
acid amide (4) and acid hydrazide (3).
1H NMR spectrum of compound (2) showed that triplet at
d 1.35 due to CH3 protons of the ethyl group and quartet
signals appeared at d 4.33 due to the CH2 protons of the ethyl
group at position 4. The 1H NMR spectra of compound
(2–15) showed singlet within the region of d 2.45–2.57 due
to methyl thiazole proton and aromatic protons appeared as
multiplets within the region of d 7.34–8.14. For compound
(3) a broad singlet peak at d 4.47 for NH2 and d 8.65 for
NH was observed. All other derivatives exhibited satisfactory
chemical shift which conﬁrmed the assigned structure of
compounds.
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4.2.1. Anti-inﬂammatory activity
Anti-inﬂammatory activity was evaluated by the carra-
geenan-induced paw edema test in rats (Winter et al.,
1962) at equimolar doses equivalent to 25 mg/kg (diclofenac
sodium) body weight. The anti-inﬂammatory activity data
(Table 1) indicated that all the test compounds protected
rats from carrageenan-induced inﬂammation moderately at
1 h of reaction time with increased activity at 3 h. The entire
compound in the series (6–15) exhibited the anti-inﬂamma-
tory activity in the range of 20–50% after 1 h, 31–58% after
2 h and 32–64% after 3 h. The compounds (10, 14 and 15)
exhibited 50%, 40% and 40% anti-inﬂammatory activity,
respectively, whereas standard diclofenac sodium showed
40% activity after 1 h of study. The same compounds
showed 60.71%, 64.28% and 50% activity after 3 h, whereas
standard diclofenac sodium exhibited 57.14% activity. It was
observed that the thiazole derivatives 10 (60.71%) and 14
(64.28%) have shown the better activity than standard
drug, diclofenac sodium (57.14%). Compounds 9 (53.57%)
and 15 (50%) showed moderate activity. The structural
correlation with anti-inﬂammatory activity showed that
the 1,3,4-oxadiazole-2(3H)-one,1,3,4-oxadiazole-2(3H)-thione
and pyrazole moiety are essential for activity. All the com-
pounds (9, 10, 14 and 15) possessing these ring moieties
exhibited activity in the range of 42.10–64.28% after 2 h
and 3 h of studies.
4.2.2. Analgesic activity
Analgesic activity was evaluated using the acetic acid induced
writhing method (Koster et al., 1959) at equimolar doses
equivalent to 25 mg/kg (diclofenac sodium) body weight using
wistar albino mice. The compounds possess signiﬁcant analge-
sic activity in the range of 21.53–62.70% (Table 2). Among the
derivatives, the compounds (9, 10, 14 and 15) showed analgesic
activity around 56.30–62.70%, whereas standard diclofenac
sodium, exhibited activity 57.96%. The compound 13 showed
moderate activity (46.67%).
4.2.3. Gastric ulcerogenic studies
The compounds which showed signiﬁcant anti-inﬂammatory
and analgesic activities have been selected for acute ulceroge-
nicity studies. Ulcerogenic effects of substituted thiazole deriv-
atives (9, 10, 14 and 15) were evaluated in rat stress model at
acute dose 25 mg/kg/day (Table 3). When compared to the ref-
erence standards diclofenac sodium (ulcer index 3.32 ± 0.74)
the test compounds exhibited 23–33% of the ulcer index of
the reference standards. The compounds (10, 14 and 15) exhib-
ited the lowest ulcer index of 0.77, 0.79 and 0.86 respectively
among the tested compounds. Incorporation 1,3,4-oxadiaz-
ole-2(3H)-thione and pyrazole at position 4 resulted into most
active and less ulcerogenic new chemical entities (NCEs) in the
series.5. Conclusion
Synthesized 5-methyl-2-phenylthiazole-4-substituted-hetero-
azole derivatives exhibited signiﬁcant analgesic and anti-
inﬂammatory activities. Compounds possessing 1,3,
4-oxadiazole-2(3H)-one, 1,3,4-oxadiazole-2(3H)-thione (9 and
10) and pyrazole (14 and 15) at position 4 of thiazole exhibited
most prominent and consistent anti-inﬂammatory activity than
the standard drug. These compounds (9, 10, 13, 14 and 15) also
showed signiﬁcant analgesia in acetic acid induced writhing
test. Interestingly tested compounds showed one-third of the
ulcer index of the reference i.e. diclofenac. These series of com-
pounds possess good potential and can be further developed
into a potent lead.Acknowledgements
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